Capricor Therapeutics (NASDAQ:CAPR) stock rose 5% in midday trading Friday after the company reported positive long-term data from a study of its drug deramiocel in the treatment of Duchenne muscular dystrophy, or DMD.

Three-year data from the study, called HOPE-2 OLE, showed